Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. - Wikidata - awgldk - TriplyDB

Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes.

Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes.

http://www.wikidata.org/entity/Q34455926

about

The secretory phospholipase A2 group IIA: a missing link between inflammation, activated renin-angiotensin system, and atherogenesis?Type II secretory phospholipase A2 and prognosis in patients with stable coronary heart disease: mendelian randomization study Noninvasive diagnosis of ruptured peripheral atherosclerotic lesions and myocardial infarction by antibody profiling A-002 (Varespladib), a phospholipase A2 inhibitor, reduces atherosclerosis in guinea pigs.Quick identification of acute chest pain patients study (QICS).Myeloperoxidase and serum amyloid A contribute to impaired in vivo reverse cholesterol transport during the acute phase response but not group IIA secretory phospholipase A(2)A lipid peroxidation product 9-oxononanoic acid induces phospholipase A2 activity and thromboxane A2 production in human blood.Functional analysis of two PLA2G2A variants associated with secretory phospholipase A2-IIA levels.Novel genetic approach to investigate the role of plasma secretory phospholipase A2 (sPLA2)-V isoenzyme in coronary heart disease: modified Mendelian randomization analysis using PLA2G5 expression levels Association between polymorphisms in phospholipase A2 genes and the plasma triglyceride response to an n-3 PUFA supplementation: a clinical trial The 763C>G Polymorphism of The Secretory PLA2IIa Gene Is Associated with Endometriosis in Iranian Women Prognostic utility of secretory phospholipase A(2) in patients with stable coronary artery disease.Periodontal microbiota and phospholipases: the Oral Infections and Vascular Disease Epidemiology Study (INVEST).Pathogen burden, cytomegalovirus infection and inflammatory markers in the risk of premature coronary artery disease in individuals of Indian origin.Distinct expression pattern of the full set of secreted phospholipases A2 in human colorectal adenocarcinomas: sPLA2-III as a biomarker candidate.Circulating n-3 fatty acids and trans-fatty acids, PLA2G2A gene variation and sudden cardiac arrest.Secretory Phospholipase A2 Is Associated with the Odds of Acute Coronary Syndromes through Elevation of Serum Amyloid-A Protein.Molecular and functional characterization of polymorphisms in the secreted phospholipase A2 group X gene: relevance to coronary artery disease Integrating soluble biomarkers and imaging technologies in the identification of vulnerable atherosclerotic patients.Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study.Elevated Type II Secretory Phospholipase A2 Increases the Risk of Early Atherosclerosis in Patients with Newly Diagnosed Metabolic Syndrome.Secreted phospholipase A2, lipoprotein hydrolysis, and atherosclerosis: integration with lipidomics From circulating biomarkers to genomics and imaging in the prediction of cardiovascular events in the general population.Update in therapeutic approaches to plaque stabilization.Biomarkers of plaque instability.Mendelian randomisation applied to drug development in cardiovascular disease: a review.The Notch pathway attenuates interleukin 1β (IL1β)-mediated induction of adenylyl cyclase 8 (AC8) expression during vascular smooth muscle cell (VSMC) trans-differentiation.Diagnostic efficacy of myeloperoxidase to identify acute coronary syndrome in subjects with chest pain.Secretory phospholipase A2 increases SR-BI-mediated selective uptake from HDL but not biliary cholesterol secretion.Lp-PLA2 et sPLA2 Mendelian Randomization Studies Promise to Shorten the Journey to FDA Approval

P2860

Q24317652-83180F78-145C-4D15-ADD8-B167DB085A99 Q28479244-DFA7CC63-0704-4BA0-A9C9-CAE3A1F36BAA Q33355010-1D8FCD1D-C35A-4437-A763-E319B6ABB546 Q33410007-D29834D4-0AA3-4E4D-A32B-641268EF469B Q33467558-4F7DDEE0-7F2D-4555-A043-504C7C7050F5 Q33741235-3A67C526-FBC4-4CF7-914F-F5317CACB6E2 Q34346520-045663A5-D0B1-4989-986A-091F13717E12 Q34373883-5986EEF9-8336-4A0A-B132-AAEF8D1E37C5 Q34418471-BC9ED231-F376-436C-8229-523C8B4D45D3 Q35125145-8E6E3BBF-E660-40F7-8C29-D20E543E8546 Q35166396-F52E4367-709D-4A7B-9A93-399BCD3E1F91 Q35627513-CAF0DC1C-FA2A-48DE-97D1-37740D9CE124 Q35748267-DD791720-CE70-48A3-9E54-CC3314CDD86E Q36091407-843E779D-D3EA-49D4-A7CC-4293C6F88F70 Q36459773-CC7B4DF8-288B-420B-B701-98655627A23F Q36686221-C0972419-4BF6-4589-A61A-BB126F699292 Q36975612-82C0611E-F90B-43A3-A480-F6815E0CF97F Q37238669-1E46198A-C4F6-4F60-BCE0-4AD712229E95 Q37277958-FB2C8CAF-BDAB-4EFA-93BF-2EE45D663E25 Q37303915-F6A54E32-224B-4C65-8071-DBFD0A6ED1B2 Q37492990-3A688FF7-29A8-4447-860D-0F33677F0473 Q37858911-A5BBD8DB-FFE4-4ABC-80C0-CED61DA22451 Q37881966-B3F017D5-730A-46D7-9EC0-60861B4BB00A Q38178537-256014D0-2FAD-4985-A628-8ED6E62FC561 Q38261198-393F19E4-F061-4E2C-B1FF-3443B864B8E1 Q38290764-415F7C87-D543-4EE7-8155-7A68371B5290 Q42255131-6796E0A7-DE2D-44FF-83BC-336A4B96161F Q44257097-00B1D75B-CC75-4095-A3D6-15DF9782B66D Q46882730-B561F28C-FDBD-4DAB-91C8-882073B2C69C Q58148425-7C34AFE2-FFA1-47AB-B2FF-68BC14561347 Q59129593-62DD01C0-3501-4099-A0DE-FB32C6CEBC91

P2860

Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes.

http://www.wikidata.org/entity/Q34455926

description

2005 nî lūn-bûn

@nan

2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Circulating secretory phosphol ...... vere acute coronary syndromes.

@ast

Circulating secretory phosphol ...... vere acute coronary syndromes.

@en

Circulating secretory phosphol ...... vere acute coronary syndromes.

@nl

type

label

Circulating secretory phosphol ...... vere acute coronary syndromes.

@ast

Circulating secretory phosphol ...... vere acute coronary syndromes.

@en

Circulating secretory phosphol ...... vere acute coronary syndromes.

@nl

prefLabel

Circulating secretory phosphol ...... vere acute coronary syndromes.

@ast

Circulating secretory phosphol ...... vere acute coronary syndromes.

@en

Circulating secretory phosphol ...... vere acute coronary syndromes.

@nl

P1433

Q34455926-5A91624B-1A7B-4C0D-8E25-2741D32513E1

P1476

Q34455926-0C24A165-FC5E-4C57-8BE7-3A824A000608

P2093

Q34455926-037EF014-8187-41B8-A91E-32323BC36D24

Q34455926-1F563E36-AA3E-40F5-86F4-0C00F71880D9

Q34455926-33C3DD97-82D1-46F9-BBBA-D1F34125BFA8

Q34455926-4CC91047-D28F-40DF-AD22-F434D59C236C

Q34455926-54C1C118-134A-472F-AC6B-F6B2C5A7FD25

Q34455926-59E0534B-26E8-4679-B60F-F804C51D0FA5

Q34455926-5DFA01AD-7C8E-4C9C-B656-4925E3CBE39D

Q34455926-A7333F2E-6559-4363-8007-DB93076D3EA6

Q34455926-B753C774-23A3-4E2F-94E6-027301AB0757

Q34455926-CC98AD6B-1099-4F4F-AA84-298186AE0AF4

P304

Q34455926-1F7D982C-A2B5-46E0-8E8B-750C3773B830

P31

Q34455926-7708DD4C-067E-41B1-98CC-0C1FEBBE494D

P356

Q34455926-7FAA4AEB-D1F8-43AB-9E66-233722E72A3D

P407

Q34455926-7B5C15C4-FB43-4792-83E5-1711B4727B81

P433

Q34455926-D6574B3E-CDF7-4ABC-B30D-18D1FC6080E5

P478

Q34455926-9CAB0489-2D4D-4412-9EED-C18B8C2CA9D3

P50

Q34455926-4FFCABA8-4CFB-499A-9209-F4DAC4D01BDF

Q34455926-601C6915-6E19-41F7-9CB0-945608AE658B

Q34455926-9B99A16E-A4A6-4A0E-AD6C-232C8A4AE163

Q34455926-C7F84220-B0F5-401B-A9EA-2BEDD0CFA7DB

P577

Q34455926-1D665A0E-6379-42BB-91D9-0B9B274F16B8

P5875

Q34455926-0B602719-AE80-4022-A7C8-EC4BC72733B3

P698

Q34455926-6FAE6181-910A-4E26-9F46-58DBF02563BD

P356

J.JACC.2005.06.056

P1433

Journal of the American College of Cardiology

P1476

Circulating secretory phosphol ...... vere acute coronary syndromes.

@en

P2093

Anne Dauphin

http://www.w3.org/2001/XMLSchema#string

Bernard Asselain

http://www.w3.org/2001/XMLSchema#string

Bénédicte Hugel

http://www.w3.org/2001/XMLSchema#string

Carla Sibella Arguelles

http://www.w3.org/2001/XMLSchema#string

Jean-Marie Freyssinet

http://www.w3.org/2001/XMLSchema#string

Jean-Philippe Collet

http://www.w3.org/2001/XMLSchema#string

Joëlle Benessiano

http://www.w3.org/2001/XMLSchema#string

Kathryn F Carruthers

http://www.w3.org/2001/XMLSchema#string

Keith A Fox

http://www.w3.org/2001/XMLSchema#string

Marie-Laure Tanguy

http://www.w3.org/2001/XMLSchema#string

P304

1249-1257

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JACC.2005.06.056

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P50

Gilles Montalescot

Joëlle Masliah

P577

2005-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7566001

http://www.w3.org/2001/XMLSchema#string

P698

16198839

http://www.w3.org/2001/XMLSchema#string